Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AEMD Aethlon Medical

Trading 02-23 14:18:07 EST

2.00

+0.01

+0.50%

High2.00	Low1.93	Vol6.86K
Open2.00	D1 Closing1.99	Amplitude3.52%
Mkt Cap2.63M	Tradable Cap2.62M	Total Shares1.32M
T/O13.48K	T/O Rate0.52%	Tradable Shares1.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AEMD","market":"US","secType":"STK","nameCN":"Aethlon Medical","latestPrice":2,"timestamp":1771874285275,"preClose":1.99,"halted":0,"volume":6855,"delay":0,"changeRate":0.005025125628140708,"floatShares":1308700,"shares":1315110,"eps":-48.46,"marketStatus":"Trading","change":0.01,"latestTime":"02-23 14:18:07 EST","open":1.9999,"high":2,"low":1.93,"amount":13483.5471315,"amplitude":0.035176,"askPrice":2.04,"askSize":128,"bidPrice":1.96,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-48.46,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.99,"preHourTrading":{"tag":"盘前","latestPrice":2.1,"preClose":1.99,"latestTime":"08:00 EST","volume":3,"amount":6.300000000000001,"timestamp":1771851607435,"change":0.11,"changeRate":0.055276,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.08,"preClose":2.01,"latestTime":"19:16 EST","volume":763,"amount":1592.374,"timestamp":1771632983296,"change":0.07,"changeRate":0.034826,"amplitude":0.039801},"volumeRatio":0.231059,"impliedVol":3.8125,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/AEMD/tweets","defaultTab":"tweets","newsList":[{"id":"2613782883","title":"Aethlon Medical to Present at Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613782883","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613782883?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:03","pubTimestamp":1771851803,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL8cqLbg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AEMD","BK4568","BK4583"],"gpt_icon":0},{"id":"2611905488","title":"Aethlon Medical Posts Q3 Results, Highlights Hemopurifier Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2611905488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611905488?lang=en_us&edition=fundamental","pubTime":"2026-02-13 06:04","pubTimestamp":1770933883,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Aethlon Medical ( ($AEMD) ). On February 12, 2026, Aethlon Medical reported results for its fiscal third quarte...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-posts-q3-results-highlights-hemopurifier-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-posts-q3-results-highlights-hemopurifier-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","LU2065732104.USD","BK4082","PRGS","BK4583","BK4568","AEMD"],"gpt_icon":0},{"id":"2611690855","title":"Aethlon Medical Q3 operating expenses up 13.6% yr/yr","url":"https://stock-news.laohu8.com/highlight/detail?id=2611690855","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611690855?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:27","pubTimestamp":1770931654,"startTime":"0","endTime":"0","summary":"Aethlon Medical Q3 operating expenses up 13.6% yr/yrOverviewMedical therapeutic firm's fiscal Q3 operating expenses rose 13.6% yr/yrOperating expenses for nine months declined 26.9% yr/yrCompany advan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL1N3Z81I3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4568","AEMD","BK4082"],"gpt_icon":0},{"id":"2611970482","title":"AEMD Q3 operating expenses rise 13.6% to USD 2.06 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2611970482","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611970482?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:16","pubTimestamp":1770931016,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc. reported its financial results for the third quarter  ended December 31, 2025. The company posted consolidated operating expenses of approximately 2.06 million ISO, reflecting a 13.6% increase, primarily due to higher payroll expenses. As of December 31, 2025, Aethlon Medical held a cash balance of about 7.0 million ISO. Total stockholders’ equity stood at 6.71 million ISO at the end of the period, while total liabilities and stockholders’ equity amounted to 8.06 million ISO. The accumulated deficit was 173.22 million ISO. Operationally, Aethlon Medical achieved a 26.9% reduction in operating expenses during the nine months ended December 31, 2025, as part of ongoing cost optimization efforts while advancing clinical and research programs. The company continues to focus on developing products targeting cancer and life-threatening infectious diseases, with CEO and CFO James Frakes highlighting recent progress in trials, research collaborations, and technology develo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL2Y7Csx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD","BK4082","BK4568","BK4583"],"gpt_icon":0},{"id":"2611704229","title":"Aethlon Medical Q3 EPS $(2.45) Beats $(2.57) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2611704229","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611704229?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:16","pubTimestamp":1770930966,"startTime":"0","endTime":"0","summary":"Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(2.45) per share which beat the analyst consensus estimate of $(2.57) by 4.67 percent. This is a 135.58 percent decrease over losses of $(1.04) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50596433/aethlon-medical-q3-eps-2-45-beats-2-57-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aethlon Medical Q3 EPS $(2.45) Beats $(2.57) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD"],"gpt_icon":0},{"id":"2611970472","title":"Press Release: Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2611970472","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611970472?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:15","pubTimestamp":1770930900,"startTime":"0","endTime":"0","summary":"Clinical and research programs continue to advance, supported by year-to-date cost efficiencies. SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc.  , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.-- Maintained Nasdaq Listing: Continued compliance with Nasdaq listing. requirements, with all prior compliance matters remaining resolved.--  Clinical Progress: Cohort 2 of the Australian oncology trial is actively. -- Scientific Advancement: Continued advancement of the Company's. COVID data published on bioRxiv and submitted for peer review, supporting. the Hemopurifier's potential as a multi-indication therapeutic approach. compatibility with a simplified blood treatment system to support broader. in lower year-to-date operating expenses compared to prior year.The Aethlon R&","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4022","R","BK4092","HP","BK4232","MTA","BK4583","AEMD","BK4188","BK4568"],"gpt_icon":0},{"id":"2608364627","title":"Aethlon Medical Inc. veröffentlicht demnächst neue Quartalszahlen und lädt zur Investorenkonferenz ein","url":"https://stock-news.laohu8.com/highlight/detail?id=2608364627","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608364627?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:02","pubTimestamp":1770210148,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL4JxXBj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD","BK4082","BK4583","BK4568"],"gpt_icon":0},{"id":"2606224451","title":"Aethlon Medical Amends Warrants to Allow Immediate Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2606224451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606224451?lang=en_us&edition=fundamental","pubTime":"2026-01-27 06:48","pubTimestamp":1769467691,"startTime":"0","endTime":"0","summary":"The latest update is out from Aethlon Medical ( ($AEMD) ). On January 22, 2026, Aethlon Medical, Inc. and an institutional investor amended a Decem...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-amends-warrants-to-allow-immediate-exercise?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-amends-warrants-to-allow-immediate-exercise?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","AEMD","BK4568","BK4082"],"gpt_icon":0},{"id":"2604191679","title":"Aethlon Medical Inc. Announces Date for Upcoming Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2604191679","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604191679?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:17","pubTimestamp":1768598220,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc. has announced that its Annual Meeting of Stockholders will be held on February 19, 2026. The meeting will address the election of director nominees and other matters that may properly come before the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLcfNyKg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4082","AEMD","BK4568"],"gpt_icon":0},{"id":"2593144880","title":"BRIEF-Aethlon Medical Inc Files For Common Stock Offering Of $15 Million, SEC Filing Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2593144880","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593144880?lang=en_us&edition=fundamental","pubTime":"2025-12-24 04:34","pubTimestamp":1766522074,"startTime":"0","endTime":"0","summary":"BRIEF-Aethlon Medical Inc Files For Common Stock Offering Of $15 Million, SEC Filing ShowsDec 23  - Aethlon Medical Inc AEMD.O:AETHLON MEDICAL INC: FILES FOR COMMON STOCK OFFERING OF $15 MILLION - SEC FILINGSource text: [ID:n0001683168-25-009335]Further company coverage: AEMD.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0AS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4568","AEMD","BK4583"],"gpt_icon":0},{"id":"2593410428","title":"Aethlon Medical Inc: Files for Common Stock Offering of $15 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2593410428","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593410428?lang=en_us&edition=fundamental","pubTime":"2025-12-24 04:08","pubTimestamp":1766520482,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0AS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4568","BK4583","AEMD"],"gpt_icon":0},{"id":"2589381847","title":"BRIEF-Aethlon Medical Announces Pricing Of A Private Placement And Warrant Inducement","url":"https://stock-news.laohu8.com/highlight/detail?id=2589381847","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589381847?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:15","pubTimestamp":1764944139,"startTime":"0","endTime":"0","summary":"BRIEF-Aethlon Medical Announces Pricing Of A Private Placement And Warrant InducementDec 5 (Reuters) - Aethlon Medical Inc AEMD.O:AETHLON MEDICAL ANNOUNCES PRICING OF A PRIVATE PLACEMENT AND WARRANT I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA9CKCYK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","AEMD","BK4082","BK4583"],"gpt_icon":0},{"id":"2589681844","title":"Press Release: Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2589681844","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589681844?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:15","pubTimestamp":1764944100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Dec. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc.  , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 595,897 shares of common stock , together with warrants to purchase up to an aggregate 1,042,820 shares of common stock, in a private placement priced at-the-market under Nasdaq rules. The combined effective offering price for each share of common stock  and accompanying warrants is $4.03. The warrants will have an exercise price of $4.03 per share, will be exercisable upon shareholder approval, and will expire on the five and one-half year anniversary from such date of shareholder approval.Maxim Group LLC is acting as the sole placement agent in connection with the offering.The offer and sale of the foregoing securities are being made in a private placement under Section 4 of the Secu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","AEMD","BK4082","BK4583"],"gpt_icon":0},{"id":"2588053472","title":"Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053472","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053472?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680572,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc. has announced the publication of preclinical data demonstrating that the GNA affinity resin in its Hemopurifier device binds to extracellular vesicles  in plasma samples from Long COVID patients and decreases inflammatory microRNAs. The results, published on November 20, 2025, in the pre-print archive bioRxiv, indicate that the Hemopurifier removes both large and small EVs, which are elevated in Long COVID patients compared to recovered controls. Additionally, NanoString analyses identified seven EV-associated microRNAs significantly reduced by treatment with the GNA affinity resin. The company stated that these findings support further investigation of the Hemopurifier in Long COVID. The results from this preclinical study have been submitted for consideration to a peer-reviewed journal and have not yet been presented in a clinical trial context.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL54kBQw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD","BK4082","BK4583","BK4568"],"gpt_icon":0},{"id":"2583188506","title":"Maxim Group Reaffirms Their Hold Rating on Aethlon Medical (AEMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583188506","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583188506?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:56","pubTimestamp":1763124968,"startTime":"0","endTime":"0","summary":"In a report released on November 12, Anthony Vendetti from Maxim Group maintained a Hold rating on Aethlon Medical. The company’s shares closed yes...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-hold-rating-on-aethlon-medical-aemd-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-hold-rating-on-aethlon-medical-aemd-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AEMD"],"gpt_icon":0},{"id":"2583583813","title":"Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2583583813","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583583813?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:16","pubTimestamp":1762982197,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc. reported financial results for its fiscal second quarter ended September 30, 2025. The company announced a 48% reduction in operating expenses, reflecting ongoing cost management efforts. As of September 30, 2025, Aethlon held a cash balance of approximately $5.8 million. The company confirmed it has resolved Nasdaq compliance matters and remains listed on the Capital Market. Operationally, recruitment is underway for Cohort 2 of the Australian oncology trial under an amended protocol. Aethlon also continues its collaboration with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal. Additionally, the company initiated evaluation of its Hemopurifier device compatibility with a simplified blood treatment system.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLbhZgRc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD","BK4583","BK4568","BK4082"],"gpt_icon":0},{"id":"2583838235","title":"Aethlon Medical Q2 EPS $(3.74) Misses $(3.66) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583838235","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583838235?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:16","pubTimestamp":1762982176,"startTime":"0","endTime":"0","summary":"Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(3.74) per share which missed the analyst consensus estimate of $(3.66) by 2.1 percent. This is a 133.75 percent decrease over losses of $(1.60) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48819392/aethlon-medical-q2-eps-3-74-misses-3-66-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Aethlon Medical Q2 EPS $(3.74) Misses $(3.66) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD"],"gpt_icon":0},{"id":"2583887285","title":"Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583887285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583887285?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:15","pubTimestamp":1762982101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA9G4VDP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4583","AEMD","BK4082"],"gpt_icon":0},{"id":"2583589299","title":"Aethlon Medical Inc - Qtrly Loss per Share $3.74","url":"https://stock-news.laohu8.com/highlight/detail?id=2583589299","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583589299?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:15","pubTimestamp":1762982101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA9G4VDP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","AEMD","BK4082","BK4568"],"gpt_icon":0},{"id":"2582327400","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2582327400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582327400?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:00","pubTimestamp":1762945200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CI&T Inc. Class A                               3Q       .10        AMC. ·Digi Intl Inc.                                  4Q       .51    4:00 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEEM","BLDP","AIRG","ABEO","ATXS","CCAP","CELC","AUTL","AMAT","MGX","ALH","CRMD","CPRT","BABA","IMRX","PYPD","AVBP","CLBT","GUTS","ALUR","AYTU","ASND","CURI","ANNX","AFYA","AFCG","CREX","ALC","TWFG","LUNG","CRMT","ACXP","RSKD","CAAP","ARX","ARCO","CSCO","AEBI","CINT","AEMD","IBTA","ABSI","ATAT","CABA","ALVO","ALMS","ARDT","AKRO","ABOS"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.aethlonmedical.com","stockEarnings":[{"period":"1week","weight":0.0255},{"period":"1month","weight":-0.2717},{"period":"3month","weight":-0.4463},{"period":"6month","weight":-0.8736},{"period":"1year","weight":-0.9588},{"period":"ytd","weight":-0.2744}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.360101},{"month":2,"riseRate":0.090909,"avgChangeRate":-0.164148},{"month":3,"riseRate":0.2,"avgChangeRate":-0.122222},{"month":4,"riseRate":0.2,"avgChangeRate":-0.105016},{"month":5,"riseRate":0.3,"avgChangeRate":-0.125643},{"month":6,"riseRate":0.8,"avgChangeRate":0.195518},{"month":7,"riseRate":0.2,"avgChangeRate":-0.085564},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.064693},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.084082},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.111246},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.001468},{"month":12,"riseRate":0.454545,"avgChangeRate":0.017294}],"exchange":"NASDAQ","name":"Aethlon Medical","nameEN":"Aethlon Medical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aethlon Medical(AEMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aethlon Medical,AEMD,Aethlon Medical股票,Aethlon Medical股票老虎,Aethlon Medical股票老虎国际,Aethlon Medical行情,Aethlon Medical股票行情,Aethlon Medical股价,Aethlon Medical股市,Aethlon Medical股票价格,Aethlon Medical股票交易,Aethlon Medical股票购买,Aethlon Medical股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aethlon Medical(AEMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction